7,623.46

+43.39

+0.57%

52,292.60

+522.29

+1.01%

25,625.59

+188.60

+0.74%

2,824.60

+12.75

+0.45%

4.8880

-0.0410

-0.83%

19.35

-0.07

-0.36%

3,968.50

+69.60

+1.79%

77,750.64

-104.24

-0.13%

Crude Oil Dec 26

97.33

-6.79

-6.52%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqCM - Nasdaq Real Time Price USD

Evogene Ltd. (EVGN)

0.3667 -0.0079 (-2.11%)

As of 9:42:32 AM EST. Market Open.

Loading Chart for EVGN

Chart Range Bar

Interval:

In partnership with ChartIQ

Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program

Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program

Evogene to Participate in Upcoming BIO-Europe in Germany and Drug Discovery Chemistry Europe in Spain

Evogene to Participate in Upcoming BIO-Europe in Germany and Drug Discovery Chemistry Europe in Spain

Evogene to Participate in U.S. East Coast AI Drug Discovery Roadshow Organized by the Israel Export Institute and TradeIL

Evogene to Participate in U.S. East Coast AI Drug Discovery Roadshow Organized by the Israel Export Institute and TradeIL

Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward

Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward

Evogene (EVGN) Q2 2026 Earnings Call Transcript

Evogene (EVGN) Q2 2026 Earnings Call Transcript

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees

Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation

Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation

Evogene and ELEO to develop new oral PCSK9 inhibitors

Evogene and ELEO to develop new oral PCSK9 inhibitors

Evogene Ltd. Q2 2026 Earnings Call Summary

Evogene Ltd. Q2 2026 Earnings Call Summary

Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors

Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors

Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance

Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance

Mobilize your Website

View Site in Mobile | Classic

Share by: